WARF: P05362US

  • Assigned to WARF as biological material.

Methods and Materials for Assaying Non-SCD1 Isoforms


James Ntambi, Makoto Miyazaki

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing useful tools for the discovery of SCD inhibitors.
OVERVIEWStearoyl-CoA desaturase (SCD) is the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids. Inhibitors of SCD may be useful therapeutics for diseases such as obesity and diabetes.
THE INVENTIONUW-Madison researchers have developed useful tools for the discovery of SCD inhibitors. The invention consists of cDNAs for murine SCD2 and SCD3 and human SCD5, along with a stable mammalian cell line and yeast strain that express human SCD5. In addition, the invention includes SCD2, and SCD3 knockout and transgenic mice, as well as the targeting constructs used to generate the SCD1 and SCD3 transgenic mice.
  • Useful in the development of SCD inhibitors
  • May lead to therapeutics for diseases such as obesity and diabetes
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.